CTMXCytomX Therapeutics, Inc.
Price
-26%1YEnd-of-day closes, not the intraday tick.
The checks lean against it
Quality shaky, a flag to check, growth fading, the market against it.
Charts
As reported to the SEC, without any scoring.
CytomX Therapeutics, Inc. (CTMX) reported revenue of $1.4M in Q2 2026 (quarter ended Jun 30, 2026), down 92% from the same quarter a year earlier. That came with net loss of $21M. For the full year FY2025, revenue was $76M (−45% year on year) and net income −$17M. The next results filing is expected around Nov 5, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 6, 2026CytomX Therapeutics Announces Q2 2026 Financial Results and Provides.Earnings release · press release
- Jul 27, 2026On July 24, 2026, Charles Fuchs, M.D., M.P.H., was appointed to the Board of Directors (the “Board”) of CytomX Therapeutics, Inc. (the “Company”), effective immediately, as a Class II director, with an initial term expiring at the Company’s 2029 annual meeting of stockholders.Director or officer change · Form 8-K
- Jun 22, 2026On June 17, 2026, stockholders of CytomX Therapeutics, Inc. (the “Company”) approved at the Company’s 2026 Annual Meeting of Stockholders (the “Annual Meeting”) an amendment (the “2015 Plan Amendment”) to the Company’s Amended and Restated 2015 Equity Incentive Plan (the “2015 Plan”) and an amendment (the “ESPP …Director or officer change · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.